Hepatitis B cure: From discovery to regulatory approval

Journal of Hepatology

Volumn 67, Issue 4, 2017, Pages 847-861

  Lok, Anna S ^a   Zoulim, Fabien ^b   Dusheiko, Geoffrey ^c   Ghany, Marc G ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Antiviral therapy; Chronic hepatitis B; Covalently closed circular DNA; Hepatitis B surface antigen; Immune modulatory therapy

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; INTERFERON; VACCINE; VIRAL PROTEIN; VIRUS RNA; HEPATITIS B VACCINE; VIRUS DNA;

ANTIVIRAL THERAPY; CLINICAL OUTCOME; GENE FUNCTION; GENE SILENCING; GENETIC TRANSCRIPTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; LIMIT OF QUANTITATION; LIVER CELL NUCLEUS; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SEROCONVERSION; VACCINATION; VIRAL CLEARANCE; VIRUS NUCLEOCAPSID; BLOOD; CHRONIC HEPATITIS B; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFECT; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; SUSTAINED VIROLOGIC RESPONSE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DNA, VIRAL; DRUG APPROVAL; DRUG DISCOVERY; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOTHERAPY; SUSTAINED VIROLOGIC RESPONSE; VIRUS REPLICATION;

EID: 85026507324     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.05.008     Document Type: Review

References (86)

1. Liaw, Y.F., Sung, J.J., Chow, W.C., Farrell, G., Lee, C.Z., Yuen, H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004), 1521–1531.
2. Bertoletti, A., Kennedy, P.T., The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol 12 (2015), 258–263.
3. Kennedy, P.T., Sandalova, E., Jo, J., Gill, U., Ushiro-Lumb, I., Tan, A.T., et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 143 (2012), 637–645.
4. Park, J.J., Wong, D.K., Wahed, A.S., Lee, W.M., Feld, J.J., Terrault, N., et al. Hepatitis B virus–specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology 150 (2016), 684–695.
5. Wu, J.F., Chiu, Y.C., Chang, K.C., Chen, H.L., Ni, Y.H., Hsu, H.Y., et al. Predictors of hepatitis B e antigen–negative hepatitis in chronic hepatitis B virus-infected patients from childhood to adulthood. Hepatology 63 (2016), 74–82.
6. Liu, J., Yang, H.I., Lee, M.H., Jen, C.L., Batri-Utermann, R., Lu, S.N., et al. Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression. Hepatology 64 (2016), 381–389.
7. Tseng, T.C., Liu, C.J., Yang, H.C., Su, T.H., Wang, C.C., Chen, C.L., et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142 (2012), 1140–1149 [Quiz e13–e14].
8. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67 (2017), 370–398.
9. Kim, G.A., Lee, H.C., Kim, M.J., Ha, Y., Park, E.J., An, J., et al. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. J Hepatol 62 (2015), 1092–1099.
10. Yuen, M.F., Wong, D.K., Fung, J., Ip, P., But, D., Hung, I., et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 135 (2008), 1192–1199.
11. Gounder, P.P., Bulkow, L.R., Snowball, M., Negus, S., Spradling, P.R., Simons, B.C., et al. Nested case–control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther 43 (2016), 1197–1207.
12. Perrillo, R.P., Martin, P., Lok, A.S., Preventing hepatitis B reactivation due to immunosuppressive drug treatments. JAMA 313 (2015), 1617–1618.
13. Chen, C.J., Yang, H.I., Su, J., Jen, C.L., You, S.L., Lu, S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006), 65–73.
14. Iloeje, U.H., Yang, H.I., Su, J., Jen, C.L., You, S.L., Chen, C.J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006), 678–686.
15. Yang, H.I., Yuen, M.F., Chan, H.L., Han, K.H., Chen, P.J., Kim, D.Y., et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 12 (2011), 568–574.
16. Papatheodoridis, G., Dalekos, G., Sypsa, V., Yurdaydin, C., Buti, M., Goulis, J., et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 64 (2016), 800–806.
17. Lee, M.H., Yang, H.I., Liu, J., Batria-Utermann, R., Jen, C.L., Iloeje, U.H., et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 58 (2013), 546–554.
18. Yuen, M.F., Tanaka, Y., Fong, D.Y., Fung, J., Wong, D.K., Yuen, J.C., et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 50 (2009), 80–88.
19. Yang, H.I., Sherman, M., Su, J., Chen, P.J., Liaw, Y.F., Iloeje, U.H., et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 28 (2010), 2437–2444.
20. Jung, K.S., Kim, S.U., Ahn, S.H., Park, Y.N., Kim, D.Y., Park, J.Y., et al. Risk assessment of hepatitis B virus–related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 53 (2011), 885–894.
21. Masuzaki, R., Tateishi, R., Yoshida, H., Goto, E., Sato, T., Ohki, T., et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 49 (2009), 1954–1961.
22. de Ledinghen, V., Vergniol, J., Barthe, C., Foucher, J., Chermak, F., Le Bail, B., et al. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus. Aliment Pharmacol Ther 37 (2013), 979–988.
23. Kim, S.U., Lee, J.H., Kim, D.Y., Ahn, S.H., Jung, K.S., Choi, E.H., et al. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One, 7, 2012, e36676.
24. Kim, J.H., Kim, J.W., Seo, J.W., Choe, W.H., Kwon, S.Y., Noninvasive tests for fibrosis predict 5-year mortality and hepatocellular carcinoma in patients with chronic hepatitis B. J Clin Gastroenterol 50 (2016), 882–888.
25. Terrault, N.A., Bzowej, N.H., Chang, K.M., Hwang, J.P., Jonas, M.M., Murad, M.H., et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63 (2016), 261–283.
26. Sarin, S.K., Kumar, M., Lau, G.K., Abbas, Z., Chan, H.L., Chen, C.J., et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10 (2016), 1–98.
27. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
28. Lok, A.S., Wu, P.C., Lai, C.L., Lau, J.Y., Leung, E.K., Wong, L.S., et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 102 (1992), 2091–2097.
29. Chan, H.L., Chan, C.K., Hui, A.J., Chan, S., Poordad, F., Chang, T.T., et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen–positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology 146 (2014), 1240–1248.
30. Yapali, S., Talaat, N., Lok, A.S., Management of hepatitis B: our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol 12 (2014), 16–26.
31. Papatheodoridis, G., Vlachogiannakos, I., Cholongitas, E., Wursthorn, K., Thomadakis, C., Touloumi, G., et al. Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology 63 (2016), 1481–1492.
32. Marcellin, P., Ahn, S.H., Ma, X., Caruntu, F.A., Tak, W.Y., Elkashab, M., et al. Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 150 (2016), 134–144.
33. Cheng, H.R., Kao, J.H., Wu, H.L., Tseng, T.C., Liu, C.H., Yang, H.C., et al. Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection. Hepatol Int 9 (2015), 35–42.
34. Seto, W.K., Wong, D.K., Fung, J., Huang, F.Y., Lai, C.L., Yuen, M.F., Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 58 (2013), 923–931.
35. Lai, C.L., Yuen, M.F., Prevention of hepatitis B virus–related hepatocellular carcinoma with antiviral therapy. Hepatology 57 (2013), 399–408.
36. Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I.M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381 (2013), 468–475.
37. Chang, T.T., Liaw, Y.F., Wu, S.S., Schiff, E., Han, K.H., Lai, C.L., et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52 (2010), 886–893.
38. Blank, A., Markert, C., Hohmann, N., Carls, A., Mikus, G., Lehr, T., et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol 65 (2016), 483–489.
39. Urban, S., Bartenschlager, R., Kubitz, R., Zoulim, F., Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 147 (2014), 48–64.
40. Lucifora, J., Xia, Y., Reisinger, F., Zhang, K., Stadler, D., Cheng, X., et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343 (2014), 1221–1228.
41. Ely, A., Moyo, B., Arbuthnot, P., Progress with developing use of gene editing to cure chronic infection with hepatitis B virus. Mol Ther 24 (2016), 671–677.
42. Seeger, C., Sohn, J.A., Complete spectrum of CRISPR/Cas9-induced mutations on HBV cccDNA. Mol Ther 24 (2016), 1258–1266.
43. Tropberger, P., Mercier, A., Robinson, M., Zhong, W., Ganem, D.E., Holdorf, M., Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc Natl Acad Sci USA 112 (2015), E5715–E5724.
44. Belloni, L., Allweiss, L., Guerrieri, F., Pediconi, N., Volz, T., Pollicino, T., et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 122 (2012), 529–537.
45. Decorsiere, A., Mueller, H., van Breugel, P.C., Abdul, F., Gerossier, L., Beran, R.K., et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature 531 (2016), 386–389.
46. Gish, R.G., Yuen, M.F., Chan, H.L., Given, B.D., Lai, C.L., Locarnini, S.A., et al. Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Res 121 (2015), 97–108.
47. Yuen, M.-F., Chan, H.L.Y., Liu, K., Given, B.D., Schluep, T., Hamilton, J., et al. Differential reductions in viral antigens expressed from cccDNA vs. integrated DNA in treatment naïve HBeAg positive and negative patients with chronic HBV after RNA interference therapy with ARC-520. J Hepatol, 64, 2016, 213.
48. Klumpp, K., Lam, A.M., Lukacs, C., Vogel, R., Ren, S., Espiritu, C., et al. High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein. Proc Natl Acad Sci USA 112 (2015), 15196–15201.
49. Venkatakrishnan, B., Katen, S.P., Francis, S., Chirapu, S., Finn, M.G., Zlotnick, A., Hepatitis B virus capsids have diverse structural responses to small-molecule ligands bound to the heteroaryldihydropyrimidine pocket. J Virol 90 (2016), 3994–4004.
50. Yuen, M.-F., Kim, D.J., Weilert, F., Chan, H.L.-Y., Lalezari, J., Hwang, S.G., et al. NVR 3-778, a first-in-class HBV core inhibitor, alone and in combination with peg-interferon (PegIFN), in treatment-naive HBeAg-positive patients: early reductions in HBV DNA and HBeAg. J Hepatol 64 (2016), LB–∗∗∗06.
51. + chronic hepatitis B infection. PLoS One, 11, 2016, e0156667.
52. Bazinet, M., Pantea, V., Placinta, G., Moscalu, I., Cebotarescu, V., Cojuhari, L., et al. Preliminary safety and efficacy of REP 2139-Mg or REP2165-Mg used in combination with tenofovir disoproxilfumarate and pegylated interferon alpha 2a in treatment naïve Caucasian patients with chronic HBeAg negative HBV infection. Hepatology 64 (2016), LB–L7.
53. Bertoletti, A., Ferrari, C., Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61 (2012), 1754–1764.
54. Tan, A., Koh, S., Bertoletti, A., Immune response in hepatitis B virus infection. Cold Spring Harb Perspect Med, 5, 2015, a021428.
55. + cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191 (2000), 1269–1280.
56. Mason, W.S., Gill, U.S., Litwin, S., Zhou, Y., Peri, S., Pop, O., et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology 151 (2016), 986–998.
57. Liu, F., Campagna, M., Qi, Y., Zhao, X., Guo, F., Xu, C., et al. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog, 9, 2013, e1003613.
58. Lau, D.T., Everhart, J., Kleiner, D.E., Park, Y., Vergalla, J., Schmid, P., et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113 (1997), 1660–1667.
59. Buster, E.H., Flink, H.J., Cakaloglu, Y., Simon, K., Trojan, J., Tabak, F., et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2 b. Gastroenterology 135 (2008), 459–467.
60. Lanford, R.E., Guerra, B., Chavez, D., Giavedoni, L., Hodara, V.L., Brasky, K.M., et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144 (2013), 1508–1517.
61. Menne, S., Tumas, D.B., Liu, K.H., Thampi, L., AlDeghaither, D., Baldwin, B.H., et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the woodchuck model of chronic hepatitis B. J Hepatol 62 (2015), 1237–1245.
62. Gane, E.J., Lim, Y.S., Gordon, S.C., Visvanathan, K., Sicard, E., Fedorak, R.N., et al. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol 63 (2015), 320–328.
63. Janssen, H.L., Brunetto, M.R., Kim, Y.J., Ferrari, C., Massetto, B., Nguyen, A.-H., et al. Safety and efficacy of GS-9620 in virally-suppressed patients with chronic hepatitis B [Abstract]. Hepatology 64 (2016), 913 A–914 A.
64. Guo, F., Han, Y., Zhao, X., Wang, J., Liu, F., Xu, C., et al. STING agonists induce an innate antiviral immune response against hepatitis B virus. Antimicrob Agents Chemother 59 (2015), 1273–1281.
65. Sato, S., Li, K., Kameyama, T., Hayashi, T., Ishida, Y., Murakami, S., et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity 42 (2015), 123–132.
66. Korolowicz, K.E., Iyer, R.P., Czerwinski, S., Suresh, M., Yang, J., Padmanabhan, S., et al. Antiviral efficacy and host innate immunity associated with SB 9200 treatment in the woodchuck model of chronic hepatitis B. PLoS One, 11, 2016, e0161313.
67. Tzeng, H.T., Tsai, H.F., Liao, H.J., Lin, Y.J., Chen, L., Chen, P.J., et al. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS One, 7, 2012, e39179.
68. Liu, J., Zhang, E., Ma, Z., Wu, W., Kosinska, A., Zhang, X., et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog, 10, 2014, e1003856.
69. Fisicaro, P., Valdatta, C., Massari, M., Loggi, E., Biasini, E., Sacchelli, L., et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138 (2010), 682–693.
70. Johnson, D.B., Balko, J.M., Compton, M.L., Chalkias, S., Gorham, J., Xu, Y., et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375 (2016), 1749–1755.
71. Gaggar, A., Coeshott, C., Apelian, D., Rodell, T., Armstrong, B.R., Shen, G., et al. Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. Vaccine 32 (2014), 4925–4931.
72. Lok, A.S., Pan, C.Q., Han, S.H., Trinh, H.N., Fessel, W.J., Rodell, T., et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol 65 (2016), 509–516.
73. Janssen, H.L., Yoon, S.K., Yoshida, E.M., Trinh, H.N., Rodell, T.C., Nguyen, A.H., et al. Safety and efficacy of GS-4774 in combination with TDF in patients with chronic hepatitis B [Abstract]. Hepatology, 64, 2016, 122 A.
74. Rehermann, B., Lau, D., Hoofnagle, J.H., Chisari, F.V., Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 97 (1996), 1655–1665.
75. Boni, C., Laccabue, D., Lampertico, P., Giuberti, T., Vigano, M., Schivazappa, S., et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 143 (2012), 963–973.
76. Hong, M., Sandalova, E., Low, D., Gehring, A.J., Fieni, S., Amadei, B., et al. Trained immunity in newborn infants of HBV-infected mothers. Nat Commun, 6, 2015, 6588.
77. Fattovich, G., Giustina, G., Realdi, G., Corrocher, R., Schalm, S.W., Long-term outcome of hepatitis B e antigen–positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 26 (1997), 1338–1342.
78. Kim, G.A., Lim, Y.S., An, J., Lee, D., Shim, J.H., Kim, K.M., et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 63 (2014), 1325–1332.
79. Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C.M., Mohr, L., et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334 (1996), 1422–1427.
80. Thompson, A.J., Nguyen, T., Iser, D., Ayres, A., Jackson, K., Littlejohn, M., et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51 (2010), 1933–1944.
81. Li, W., Zhao, J., Zou, Z., Liu, Y., Li, B., Sun, Y., et al. Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-naive patients with acute and chronic HBV infection. PLoS One, 9, 2014, e89046.
82. Manesis, E.K., Papatheodoridis, G.V., Tiniakos, D.G., Hadziyannis, E.S., Agelopoulou, O.P., Syminelaki, T., et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol 55 (2011), 61–68.
83. van Bommel, F., Bartens, A., Mysickova, A., Hofmann, J., Kruger, D.H., Berg, T., et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 61 (2015), 66–76.
84. Wang, J., Shen, T., Huang, X., Kumar, G.R., Chen, X., Zeng, Z., et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol 65 (2016), 700–710.
85. Jung, K.S., Park, J.Y., Chon, Y.E., Kim, H.S., Kang, W., Kim, B.K., et al. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol 51 (2016), 830–839.
86. Suzuki, F., Miyakoshi, H., Kobayashi, M., Kumada, H., Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 81 (2009), 27–33.